FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3208585975> ?p ?o ?g. }

• W3208585975 endingPage "S77" @default.
• W3208585975 startingPage "S77" @default.
• W3208585975 abstract "Prostatectomy (RP) is a treatment (tx) option even for high-risk prostate cancer (PC) per the NCCN guidelines. We report the long-term follow-up of a pilot clinical trial using an aggressive multimodal approach integrating chemo-hormone tx, prostatectomy (RP) and adjuvant radiation (RT) in men with high/very high-risk PC.Preoperative tx entailed 6 months (mo) of chemo-hormones consisting of LHRH agonist (6 mo) integrated with adriamycin (A) and docetaxel (T). Two dose levels of A and T were incorporated with LHRH agonist tx: a higher dose (HD) of A (50mg/m2) and T (70mg/m2), and a lower dose (LD) of A (15mg/m2) and T (30mg/m2). HD chemo was given on 2 separate occasions (3 days post LHRH injection) in an effort to take advantage of the expected testosterone surge that occurs 3-5 days post LHRH agonist tx, while LD chemotherapy was given at other time points during the 6-month neoadjuvant period. This was followed by RP. The median post-op RT dose was 70.2 Gy (whole pelvis, with cone downs; range: 64.8-70.2) via 3D-CRT/IMRT. Three patients did not undergo RP after neoadjuvant chemo-hormone tx and went on to receive definitive RT (75.6 Gy). The overall survival (OS), disease-free survival (DFS), freedom from PSA failure (bNED, PSA > 0.2), and late GI/GU toxicity rates were calculated using the Kaplan-Meier method.A total of 22 men were enrolled from 2002-2006. Median pre-tx age, PSA and Gleason score were 61 years (range, 43-70), 24.1 ng/ml (range, 1.6-168.3) and 7 (range, 6-10), respectively. A total of 77% of patients received all therapy as planned. Median follow-up for the entire cohort and those alive were 10.9 years (range, 3.4-18.4) and 16.8 years (range, 15-18.4), respectively. The 15-year OS, DFS and bNED rates were 31.2%, 22.7% and 46.2%, respectively. Six patients (27%) never achieved PSA < 0.2. Worst acute grade 3 and 4 toxicity rates were 68% and 32%, respectively. The 15-year actuarial grade 3 or worse late GU toxicity rate was 13%. There was no grade 3 or worse late GI toxicities and no grade 5 acute or late toxicity.Despite an aggressive multimodal regimen that incorporated chemo-hormones, RP and adjuvant RT for high/very high-risk prostate cancer, the 15-year bNED rate was only 46.5%. Therefore, the role of RP and neoadjuvant chemo-hormone therapy remains questionable among high-risk patients in light of superior long-term outcomes demonstrated in trials like ASCENDE-RT that incorporated brachytherapy boost with RT and androgen deprivation." @default.
• W3208585975 created "2021-11-08" @default.
• W3208585975 creator A5004160237 @default.
• W3208585975 creator A5024145910 @default.
• W3208585975 creator A5052573263 @default.
• W3208585975 creator A5075165181 @default.
• W3208585975 date "2021-11-01" @default.
• W3208585975 modified "2023-10-16" @default.
• W3208585975 title "A Prospective Trial of Aggressive Therapy Consisting of Neoadjuvant Chemotherapy and Androgen Deprivation Followed by Prostatectomy and Adjuvant Radiation in High/Very High-Risk Prostate Cancer" @default.
• W3208585975 doi "https://doi.org/10.1016/j.ijrobp.2021.07.188" @default.
• W3208585975 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34700631" @default.
• W3208585975 hasPublicationYear "2021" @default.
• W3208585975 type Work @default.
• W3208585975 sameAs 3208585975 @default.
• W3208585975 citedByCount "0" @default.
• W3208585975 crossrefType "journal-article" @default.
• W3208585975 hasAuthorship W3208585975A5004160237 @default.
• W3208585975 hasAuthorship W3208585975A5024145910 @default.
• W3208585975 hasAuthorship W3208585975A5052573263 @default.
• W3208585975 hasAuthorship W3208585975A5075165181 @default.
• W3208585975 hasBestOaLocation W32085859751 @default.
• W3208585975 hasConcept C121608353 @default.
• W3208585975 hasConcept C126322002 @default.
• W3208585975 hasConcept C126894567 @default.
• W3208585975 hasConcept C143998085 @default.
• W3208585975 hasConcept C2776694085 @default.
• W3208585975 hasConcept C2777863537 @default.
• W3208585975 hasConcept C2777899217 @default.
• W3208585975 hasConcept C2778043895 @default.
• W3208585975 hasConcept C2778559712 @default.
• W3208585975 hasConcept C2779279991 @default.
• W3208585975 hasConcept C2779322244 @default.
• W3208585975 hasConcept C2779466945 @default.
• W3208585975 hasConcept C2780192828 @default.
• W3208585975 hasConcept C2781190966 @default.
• W3208585975 hasConcept C509974204 @default.
• W3208585975 hasConcept C71924100 @default.
• W3208585975 hasConceptScore W3208585975C121608353 @default.
• W3208585975 hasConceptScore W3208585975C126322002 @default.
• W3208585975 hasConceptScore W3208585975C126894567 @default.
• W3208585975 hasConceptScore W3208585975C143998085 @default.
• W3208585975 hasConceptScore W3208585975C2776694085 @default.
• W3208585975 hasConceptScore W3208585975C2777863537 @default.
• W3208585975 hasConceptScore W3208585975C2777899217 @default.
• W3208585975 hasConceptScore W3208585975C2778043895 @default.
• W3208585975 hasConceptScore W3208585975C2778559712 @default.
• W3208585975 hasConceptScore W3208585975C2779279991 @default.
• W3208585975 hasConceptScore W3208585975C2779322244 @default.
• W3208585975 hasConceptScore W3208585975C2779466945 @default.
• W3208585975 hasConceptScore W3208585975C2780192828 @default.
• W3208585975 hasConceptScore W3208585975C2781190966 @default.
• W3208585975 hasConceptScore W3208585975C509974204 @default.
• W3208585975 hasConceptScore W3208585975C71924100 @default.
• W3208585975 hasIssue "3" @default.
• W3208585975 hasLocation W32085859751 @default.
• W3208585975 hasLocation W32085859752 @default.
• W3208585975 hasOpenAccess W3208585975 @default.
• W3208585975 hasPrimaryLocation W32085859751 @default.
• W3208585975 hasRelatedWork W2031872385 @default.
• W3208585975 hasRelatedWork W2127332877 @default.
• W3208585975 hasRelatedWork W2188582108 @default.
• W3208585975 hasRelatedWork W2299690226 @default.
• W3208585975 hasRelatedWork W2421909196 @default.
• W3208585975 hasRelatedWork W2909802736 @default.
• W3208585975 hasRelatedWork W3001756388 @default.
• W3208585975 hasRelatedWork W3139576587 @default.
• W3208585975 hasRelatedWork W3203253516 @default.
• W3208585975 hasRelatedWork W4295905569 @default.
• W3208585975 hasVolume "111" @default.
• W3208585975 isParatext "false" @default.
• W3208585975 isRetracted "false" @default.
• W3208585975 magId "3208585975" @default.
• W3208585975 workType "article" @default.